[Therapeutic prospects and lymphoproliferative syndromes related to EBV].
The B lymphoproliferative disorders are a major (10%) and severe (70% mortality) complication of immunosuppression required for HLA-mismatched bone marrow or organ transplantation. An experimental model was developed in which patients infected EBV-B cells are inoculated into scid mice and develop into tumors, allowing evaluation of treatment efficacy: monoclonal antibodies directed to membrane antigens of tumoral cells (monoclonal antibodies anti-B), monoclonal antibodies neutralizing interleukins (and especially IL6), cytotoxic T cells. Results obtained with these three different approaches are herein reported.
Durandy
A
A
INSERM U429, Hôpital Necker-Enfants Malades, Paris.
D000818:Animals; D005544:Forecasting; D004854:Herpesvirus 4, Human; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000209:etiology / Q000628:therapy / Q000821:virology*; D051379:Mice; D014180:Transplantation / Q000009:adverse effects
Perspectives thérapeutiques des syndromes lymphoprolifératifs liés à l'EBV.